C.E.S. TABLET
Country: Kanada
Bahasa: Inggeris
Sumber: Health Canada
Ciri produk
(SPC)
23-09-2020
Beberapa dokumen untuk produk ini saat ini tidak tersedia, anda dapat mengirim permintaan ke layanan pelanggan kami dan kami akan memberitahu Anda segera setelah kami dapat memperolehnya.
Hantar permintaan.
Hantar permintaan.
Bahan aktif:
CONJUGATED ESTROGENS
Boleh didapati daripada:
BAUSCH HEALTH, CANADA INC.
Kod ATC:
G03CA57
INN (Nama Antarabangsa):
CONJUGATED ESTROGENS
Dos:
0.625MG
Borang farmaseutikal:
TABLET
Komposisi:
CONJUGATED ESTROGENS 0.625MG
Laluan pentadbiran:
ORAL
Unit dalam pakej:
100/1000
Jenis preskripsi:
Prescription
Kawasan terapeutik:
ESTROGENS
Ringkasan produk:
Active ingredient group (AIG) number: 0106442006; AHFS:
Status kebenaran:
APPROVED
Tarikh kebenaran:
2020-09-23
Ciri produk
PRODUCT MONOGRAPH
PR
C.E.S.
Conjugated Estrogens Tablets, CSD
0.625 mg
ESTROGEN
BAUSCH HEALTH, CANADA INC.
DATE OF REVISION:
2150 St-Elzear Blvd. West
September 23, 2020
Laval, Quebec
H7L 4A8
Control No.: 242944
_Pr_
_C.E.S._
_®_
_ Product Monograph Page 2 of 33_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
..................................................................................................12
DRUG INTERACTIONS
..................................................................................................14
DOSAGE AND ADMINISTRATION
..............................................................................16
OVERDOSAGE
................................................................................................................17
ACTION AND CLINICAL PHARMACOLOGY
............................................................18
STORAGE AND STABILITY
..........................................................................................20
SPECIAL HANDLING INSTRUCTIONS
.......................................................................20
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................21
PART II: SCIENTIFIC INFORMATION
...............................................................................22
PHARMACEUTICAL INFORMATION
..........................................................................22
CLINICAL TRIALS
..........................................................................................................24
DETAIL
Baca dokumen lengkap
